Ebola vaccine spray trial halted early – what we learned
NCT ID NCT03462004
First seen Mar 20, 2026 · Last updated May 07, 2026 · Updated 6 times
Summary
This early-stage study tested a nasal spray vaccine against Ebola in 15 healthy adults. The vaccine uses a weakened common cold virus to deliver a piece of the Ebola virus, aiming to teach the body to fight off infection. The trial was stopped early, but researchers were checking for side effects and whether the vaccine triggered an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CIR Inpatient Unit, Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland, 21205, United States
Conditions
Explore the condition pages connected to this study.